Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Neurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, ...

Sarasota Memorial Hospital is one of ten research sites studying a new device to reduce bleeding complications in hemodialysis patients. The InnAVasc graft allows for immediate hemodialysis after ...

Prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for ...

Traws Pharma, Inc. (NASDAQ: TRAW) shared encouraging findings on its investigational antiviral drug, tivoxavir marboxil (TXM) ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Preclinical data with the investigational gene therapy INS1202 show improvements in survival and motor performance in ALS.

Potent Antiviral Activity in Preclinical Challenge Model: Results from a rodent challenge model showed that 100% of mice ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...